Recent News

• 08.12.2025 - Calidi Biotherapeutics Reports Second Quarter 2025 Financial Results and Recent Operational Highlights
• 07.29.2025 - Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
• 07.25.2025 - Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

Recent Filings

• 08.08.2025 - 8-K Current report
• 08.08.2025 - EX-99.1 EX-99.1
• 08.08.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.07.2025 - 8-K Current report
• 07.25.2025 - EX-99.1 EX-99.1
• 07.25.2025 - EFFECT Notice of Effectiveness
• 07.25.2025 - 8-K Current report
• 07.18.2025 - S-3 Registration statement under Securities Act of 1933
• 07.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.15.2025 - 4 Statement of changes in beneficial ownership of securities